These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical overview of the taxanes. Goldspiel BR Pharmacotherapy; 1997; 17(5 Pt 2):110S-125S. PubMed ID: 9322878 [TBL] [Abstract][Full Text] [Related]
5. Risks and benefits of taxanes in breast and ovarian cancer. Michaud LB; Valero V; Hortobagyi G Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347 [TBL] [Abstract][Full Text] [Related]
6. The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review. Mody MD; Gill HS; Saba NF JAMA Otolaryngol Head Neck Surg; 2016 Sep; 142(9):898-905. PubMed ID: 27389786 [TBL] [Abstract][Full Text] [Related]
7. Role of taxanes in adjuvant therapy. Münster PN; Hudis CA Cancer Invest; 2000; 18(1):32-8. PubMed ID: 10701365 [No Abstract] [Full Text] [Related]
8. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Goble S; Bear HD Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604 [TBL] [Abstract][Full Text] [Related]
9. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Sparano JA Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388 [TBL] [Abstract][Full Text] [Related]
10. Taxanes in lung cancer: a review with focus on the European experience. Calderoni A; Cerny T Crit Rev Oncol Hematol; 2001 May; 38(2):105-27. PubMed ID: 11311658 [TBL] [Abstract][Full Text] [Related]
11. The role of taxanes in the treatment of breast cancer. Capri G; Tarenzi E; Fulfaro F; Gianni L Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849 [TBL] [Abstract][Full Text] [Related]
12. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer. Adjei AA; Argiris A; Murren JR Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007 [TBL] [Abstract][Full Text] [Related]
13. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Chu Q; Vincent M; Logan D; Mackay JA; Evans WK; Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391 [TBL] [Abstract][Full Text] [Related]
14. Docetaxel and radiation as combined-modality therapy. Kim ES; Khuri FR Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):97-105. PubMed ID: 12108904 [TBL] [Abstract][Full Text] [Related]
15. Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Clemons M; Leahy M; Valle J; Jayson G; Ranson M; Howell A Eur J Cancer; 1997 Nov; 33(13):2183-93. PubMed ID: 9470804 [No Abstract] [Full Text] [Related]
16. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Rowinsky EK Annu Rev Med; 1997; 48():353-74. PubMed ID: 9046968 [TBL] [Abstract][Full Text] [Related]
17. [Association of taxanes and radiotherapy: preclinical and clinical studies]. Hennequin C Cancer Radiother; 2004 Nov; 8 Suppl 1():S95-105. PubMed ID: 15679254 [TBL] [Abstract][Full Text] [Related]
18. The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review. Hong WK Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):9-15. PubMed ID: 12108903 [TBL] [Abstract][Full Text] [Related]
19. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck. Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168 [TBL] [Abstract][Full Text] [Related]
20. Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled? Brockstein B Curr Opin Oncol; 2000 May; 12(3):221-8. PubMed ID: 10841194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]